{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:23:47Z","timestamp":1790652227777,"version":"4.1.0"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1001\/jamaoncol.2017.4695","type":"journal-article","created":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T12:51:19Z","timestamp":1516279879000},"page":"1106","source":"Crossref","is-referenced-by-count":177,"title":["Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2"],"prefix":"10.1001","volume":"4","author":[{"given":"Amir T.","family":"Fathi","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology and Medical Oncology, Massachusetts General Hospital Cancer Center"},{"name":"Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kline","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Kenvin","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal C.","family":"Attar","sequence":"additional","affiliation":[{"name":"Agios Pharmaceuticals, Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[{"name":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"de Botton","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the AG221-C-001 Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"cbr170035r1","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood-2016-09-670224","article-title":"Myeloid malignancies and microenvironment.","volume":"129","author":"Korn","year":"2017","journal-title":"Blood"},{"issue":"20","key":"cbr170035r2","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1182\/blood-2012-01-402545","article-title":"Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3\/ITD AML.","volume":"120","author":"Sexauer","year":"2012","journal-title":"Blood"},{"issue":"6","key":"cbr170035r3","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"1","key":"cbr170035r4","doi-asserted-by":"publisher","first-page":"e2011059","DOI":"10.4084\/mjhid.2011.059","article-title":"The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature.","volume":"3","author":"Montesinos","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"cbr170035r5","first-page":"90","article-title":"Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome.","volume":"95","author":"Tallman","year":"2000","journal-title":"Blood"},{"issue":"8","key":"cbr170035r6","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1101\/gad.217406.113","article-title":"What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.","volume":"27","author":"Losman","year":"2013","journal-title":"Genes Dev"},{"issue":"6","key":"cbr170035r7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"5","key":"cbr170035r8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations.","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov"},{"issue":"6","key":"cbr170035r9","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"issue":"8","key":"cbr170035r10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.clml.2016.04.006","article-title":"Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120.","volume":"16","author":"Birendra","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"20","key":"cbr170035r12","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"24","key":"cbr170035r13","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"13","key":"cbr170035r15","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.2000.18.13.2620","article-title":"Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.","volume":"18","author":"Camacho","year":"2000","journal-title":"J Clin Oncol"},{"key":"cbr170035r16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3324\/haematol.2015.128470","article-title":"Pharmacokinetic\/pharmacodynamic (PK\/PD) evaluation of AG-221, a potent mutant IDH2 inhibitor, from a phase 1 trial of patients with IDH2 mutation-positive hematologic malignancies","volume":"100","author":"Fan","year":"2015","journal-title":"Haematologica"},{"key":"cbr170035r11","unstructured":"Medical Dictionary for Regulatory Activities. https:\/\/www.meddra.org\/. Accessed November 8, 2017."},{"key":"cbr170035r14","unstructured":"National Institutes of Health and National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), v4.0. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Updated June 14, 2010. Accessed November 17, 2017."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2669774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T15:59:31Z","timestamp":1533830371000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2017.4695"}},"subtitle":["Analysis of a Phase 1\/2 Study"],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2017.4695","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}